HENGRUI PHARMA (01276.HK) Latest Stock News - Major News Analysis

Quote List Quote List

Event Tracking

Dec30

Hengrui Medicine Approved to Conduct Clinical Trials on Six Drugs

05:13

Dec29

Hengrui Medicine Subsidiary Obtains Clinical Trial Approval for HRS-6257

10:01

Dec28

Huahai Pharmaceutical and Shanghai Huahai's SHR-A1904 Injection Listed as Breakthrough Therapy

10:24

Hengrui Medicine Subsidiary Entrusts Hansoh Pharmaceutical for Palocabigine Soft Capsule Commercialization

08:39

Dec24

Hengrui Medicine’s SHR-A1904 Injection Included in Breakthrough Therapy List

08:56

Hengrui Medicine Subsidiary's SHR-A2102 Receives Clinical Trial Approval from NMPA

08:47

Schedules & Filings

Schedules

Filings

Oct27

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 8.119 B, Net Income 1.422 B, EPS 0.2131

Aug20

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 9.364 B, Net Income 2.82 B, EPS 0.4359

May23

IPO(CST)

Listing Price HKD 44.05

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change